TRIPLE NEGATIVE BREAST CANCER

This study is testing an experimental drug called Dato-DXd in Chinese patients with advanced non-small cell lung cancer or triple-negative breast cancer that has stopped responding to standard treatments. The drug is given as an IV infusion every three weeks to see if it can shri…

This study is testing whether a new drug called BL-B01D1 works better than standard chemotherapy for people with advanced triple-negative breast cancer that has stopped responding to taxane chemotherapy. About 418 adults who have had 1-2 prior chemotherapy treatments will be rand…

This study is testing a new combination of two immunotherapy drugs (tiragolumab and atezolizumab) with standard chemotherapy for triple-negative breast cancer. It aims to see if this three-part treatment is safe and more effective at shrinking tumors before surgery for early-stag…

This study is testing a new drug called FDA018-ADC for people with advanced triple-negative breast cancer that has returned or worsened after standard taxane chemotherapy. It will compare the new drug to standard chemotherapy options chosen by the patient's doctor. The main goals…

This early-phase study is testing a personalized cell therapy for advanced triple-negative breast cancer that has returned or stopped responding to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to recognize cancer, and infuse them back to at…

This is the first time a new drug called DS-1062a is being tested in people. The main goal is to find a safe and tolerable dose for patients with advanced solid tumors, including lung and breast cancers, that have not responded to standard treatments. The study will also test if …

This study is testing whether adding a targeted dose of radiation to the breast tumor before starting standard chemotherapy and an immunotherapy drug (pembrolizumab) makes the treatment more effective. It is for people with breast cancer that has spread to lymph nodes and is eith…

This study aimed to test the safety and effectiveness of a two-drug combination (Ezabenlimab and BI 907828) for people with advanced, hard-to-treat cancers that had spread. It was designed for adults with specific types of soft tissue sarcoma, lung, breast, colorectal, or biliary…

This early-stage study is testing an experimental drug called ABBV-400 in adults with advanced solid tumors that have spread or cannot be removed by surgery. It includes eight specific cancer types, such as liver, pancreatic, and certain breast cancers. The main goals are to chec…

This is a first-in-human study to find a safe dose and see how the body processes a new oral drug called ATV-1601. It is being tested in adults with advanced solid tumors, including certain breast cancers, that have a specific genetic change called an AKT1 E17K mutation. The main…

This study is testing a new three-drug combination given before surgery for early-stage triple-negative breast cancer (TNBC), an aggressive type. The goal is to see if adding two newer drugs (sintilimab and anlotinib) to standard chemotherapy can better shrink or eliminate the tu…

This study is testing a new drug called azenosertib, combined with two existing cancer drugs, for people with advanced triple-negative breast cancer that has spread. The main goals are to find a safe dose and see if the combination makes tumors shrink. About 78 participants will …

This study is testing a personalized cell therapy called LN-145 for patients with advanced cancers that have stopped responding to standard treatments. Doctors collect a patient's own immune cells from their tumor, grow large numbers of them in a lab, and then infuse them back in…

This early-stage study is testing the safety of a new cancer vaccine called PVX-410, given alone and with an immunotherapy drug (pembrolizumab), in 20 patients with advanced triple-negative breast cancer. The goal is to see if the combination can safely help the patient's own imm…

This study is testing if a new drug combination works better than current standard treatments for people with a hard-to-treat type of advanced breast cancer. It involves 443 adults with triple-negative breast cancer that has spread and who have not yet received treatment for thei…

This study is testing whether an experimental drug called SKB264 works better than standard chemotherapy for people with advanced triple-negative breast cancer that has continued to grow despite at least two prior treatments. The trial will involve about 254 adults whose cancer c…

This is an early-stage study testing a new drug called DKY709, both alone and combined with another drug (PDR001), in adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find safe doses and understand side effects. Researcher…

This study is testing whether a three-part treatment is safe and can help control advanced triple-negative breast cancer that has spread and hasn't responded well to standard immunotherapy. The treatment combines two drugs—one that helps the immune system fight cancer and another…

This study tests whether a combination of three drugs (pembrolizumab, carboplatin, and paclitaxel) given before surgery can completely eliminate cancer in patients with early-stage triple-negative breast cancer. The trial involves 30 participants who haven't had previous cancer t…

This early-stage study is testing a new drug called BT5528 in people with advanced solid tumors that have spread or returned. The main goals are to find a safe dose, understand the side effects, and see if the drug shows early signs of helping to control cancers like ovarian, lun…

This study is testing a combination of three drugs—cisplatin, romidepsin, and nivolumab—for people with advanced triple-negative breast cancer or breast cancer linked to a BRCA gene mutation. The goal is to see if this combination is safe and can help control the cancer in patien…

This study is testing a new drug called BNT327, given alongside standard chemotherapy, for people with advanced triple-negative breast cancer. The main goals are to see if the combination is safe and if it helps shrink tumors. The trial will enroll about 83 adults who have either…

This study is testing whether a newer drug called sacituzumab govitecan works better than standard chemotherapy for people with advanced triple-negative breast cancer. It's for patients whose cancer has spread and either doesn't respond to certain immunotherapies or who have alre…

This study is testing whether two existing oral drugs, ribociclib and bicalutamide, work better together to control advanced triple-negative breast cancer that has spread. The trial involves about 37 people whose cancer has a specific marker (the androgen receptor). The main goal…

This early-stage trial is testing the safety and finding the right dose of a two-drug combination (naptumomab estafenatox and durvalumab) for people with advanced or metastatic solid tumors. It will enroll about 120 adults with one of many eligible cancer types, including breast,…

This study is testing the safety of a drug called niraparib when given alongside standard radiation therapy after surgery. It involves 21 adults with triple-negative breast cancer who still have some cancer cells left after initial treatment. The goal is to see if this combinatio…

This is an early-stage study testing a new antibody drug called IMT-009 in people with advanced solid tumors or lymphomas that have stopped responding to standard treatments. The main goals are to find a safe dose, understand the side effects, and see if the drug helps shrink tum…

This early-stage trial is testing a new antibody drug called acasunlimab (GEN1046) for people with advanced solid tumors. The study first aims to find safe doses, then tests how well those doses work when given alone or combined with other cancer drugs. All 429 participants will …

This study is testing whether using a precise, high-dose radiation treatment on a few new or growing tumors can help people with advanced lung or breast cancer stay on their current medications longer. It aims to see if this approach can delay the cancer from getting worse. The t…

This is an early safety study testing a new cancer vaccine called PeptiCRAd-1, given alongside the immunotherapy drug pembrolizumab. It aims to see if this combination is safe and can activate the immune system to fight cancer in patients with advanced solid tumors that have stop…

This study is for people with HER2-negative breast cancer who still have cancer cells after completing standard chemotherapy before surgery, which puts them at high risk of the cancer returning. It compares a newer targeted drug called sacituzumab govitecan against the doctor's u…

This study aims to find patterns in blood proteins and other markers that might predict if triple-negative breast cancer will spread or return after initial treatment. Researchers will collect blood samples from 90 patients at different points during their standard cancer care to…

This study aims to find a way to predict which patients with triple-negative breast cancer are most likely to have their cancer return after treatment. Researchers will check the blood of 15 patients during their radiation therapy, looking for specific signals (cytokines) that mi…

This study aims to find out if simple blood tests and tumor tissue analysis can help predict how patients with triple negative breast cancer will respond to treatment and their risk of the cancer returning. Researchers will observe 90 patients to see if certain blood cell counts …

This study aims to understand how doctors currently treat advanced triple-negative breast cancer in real-world settings outside the United States. Researchers will review medical records of 760 patients from Canada, the UK, France, and Spain to document treatment patterns and pat…